- Home
- CATX vs DMAC Comparison
CATX vs DMAC Comparison
Compare CATX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- DMAC
- Stock Information
- Founded
- CATX 1983
- DMAC 2000
- Country
- CATX United States
- DMAC United States
- Employees
- CATX N/A
- DMAC N/A
- Industry
- CATX Medical/Dental Instruments
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- DMAC Health Care
- Exchange
- CATX Nasdaq
- DMAC Nasdaq
- Market Cap
- CATX 182.9M
- DMAC 158.1M
- IPO Year
- CATX N/A
- DMAC N/A
- Fundamental
- Price
- CATX $2.42
- DMAC $4.23
- Analyst Decision
- CATX Strong Buy
- DMAC Strong Buy
- Analyst Count
- CATX 9
- DMAC 2
- Target Price
- CATX $12.63
- DMAC $8.00
- AVG Volume (30 Days)
- CATX 749.8K
- DMAC 102.4K
- Earning Date
- CATX 05-12-2025
- DMAC 05-13-2025
- Dividend Yield
- CATX N/A
- DMAC N/A
- EPS Growth
- CATX N/A
- DMAC N/A
- EPS
- CATX N/A
- DMAC N/A
- Revenue
- CATX $1,471,000.00
- DMAC N/A
- Revenue This Year
- CATX N/A
- DMAC N/A
- Revenue Next Year
- CATX N/A
- DMAC N/A
- P/E Ratio
- CATX N/A
- DMAC N/A
- Revenue Growth
- CATX N/A
- DMAC N/A
- 52 Week Low
- CATX $1.60
- DMAC $2.14
- 52 Week High
- CATX $16.55
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- CATX 53.99
- DMAC 51.10
- Support Level
- CATX $2.53
- DMAC $4.00
- Resistance Level
- CATX $2.77
- DMAC $4.33
- Average True Range (ATR)
- CATX 0.28
- DMAC 0.27
- MACD
- CATX 0.00
- DMAC 0.02
- Stochastic Oscillator
- CATX 58.93
- DMAC 50.71
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.